))
Ep. 07: Use of T cell receptors (TCR’s) as immunotherapy against cancer
Manage episode 393086195 series 3485261
Indhold leveret af The Nordic Cell Therapy Podcast and KITE Gilead. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af The Nordic Cell Therapy Podcast and KITE Gilead eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
In this episode we interview Dr. Johanna Olweus and Dr. Morten Milek Nielsen from University of Oslo about the use of T cell receptors (TCR’s) as immunotherapy against cancer.
Dr. Olweus’s group has been speadheading identifying TCRs that are specific for minute mutations in cancer cells, that can be used in adoptive T-cell-based therapies. We talk about what the therapy entails, how TCRs are discovered and go through several papers her group has published recently on using TCR-based therapies against leukemia.
The articles discussed are:
- “Induction of neoantigen-reactive T cells from healthy donors” (link: https://pubmed.ncbi.nlm.nih.gov/31101906/)
- “T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes” (Link: https://www.nature.com/articles/s41587-021-01089-x)
- “A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo” (Link: https://www.nature.com/articles/s43018-023-00642-8)
- “A systematic safety pipeline for selection of T-cell receptors to enter clinical use” (Link: https://pubmed.ncbi.nlm.nih.gov/37607971/)
You can read more about Dr. Olweus research group here: https://www.ous-research.no/olweus/
7 episoder
Del
